Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study - Pipe, S W; Shima, M; Lehle, M (Lancet Haematol, 2019)